SLDB Solid Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SLDB

Price (delayed)

$7.83

Market cap

$770.86M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.95

Enterprise value

$493.79M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 4

Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by ...

Highlights
SLDB's quick ratio has surged by 123% since the previous quarter and by 18% year-on-year
The equity has surged by 108% since the previous quarter and by 27% year-on-year
The net income fell by 37% YoY and by 10% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://solidbio.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of SLDB

SLDB stock price

How has the Solid Biosciences stock price performed over time
Intraday
-1.88%
1 week
-10.21%
1 month
-15.35%
1 year
17.22%
YTD
38.83%
QTD
-21.62%

Financial performance

How have Solid Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$196.46M
Net income
-$191.78M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 37% year-on-year and by 10% since the previous quarter
The net income fell by 37% YoY and by 10% QoQ

Price vs fundamentals

How does SLDB's price correlate with its fundamentals

Growth

What is Solid Biosciences's growth rate over time

Valuation

What is Solid Biosciences stock price valuation
P/E
N/A
P/B
2.06
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 35% year-on-year and by 2% since the previous quarter
The equity has surged by 108% since the previous quarter and by 27% year-on-year
The price to book (P/B) is 87% more than the 5-year quarterly average of 1.1 and 3% more than the last 4 quarters average of 2.0

Efficiency

How efficient is Solid Biosciences business performance
The ROIC is down by 14% YoY and by 12% QoQ
The return on assets has declined by 8% year-on-year and by 3% since the previous quarter
Solid Biosciences's return on equity has decreased by 6% YoY

Dividends

What is SLDB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SLDB.

Financial health

How did Solid Biosciences financials performed over time
SLDB's quick ratio has surged by 123% since the previous quarter and by 18% year-on-year
Solid Biosciences's current ratio has surged by 113% QoQ and by 20% YoY
The debt is 94% lower than the equity
The equity has surged by 108% since the previous quarter and by 27% year-on-year
The debt to equity has plunged by 50% from the previous quarter and by 25% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.